SUMITOMO PHARMA ASIA PACIFIC PTE. LTD.

Business Description

SUMITOMO PHARMA ASIA PACIFIC PTE. LTD. is registered as a business entity on 17 January 2013 (12.1 years ago) structured as a Private Company Limited By Shares (Local Company) with 5 officer(s) in-charge. The business jurisdiction is overseen by the Accounting and Corporate Regulatory Authority (ACRA), a government agency from Singapore with the given Business Registration Number / Unique Entity Number (UEN) 201301863R. The business official address is located at 3 Fraser Street #07-28, Duo Tower, Singapore 189352 with main trading activity as Liaison Office & Regional Headquarter, South East Asia & Its Surrounding Area in the primary industry of 70101: Activities Of Head And Regional Head Offices; Centralised Administrative Offices And Subsidiary Management Offices using Singapore Dollars - SGD as its default trading currency. The business legal name has undergone change(s) and is previously known as SUNOVION PHARMACEUTICALS ASIA PACIFIC PTE. LTD., SUMITOMO PHARMACEUTICALS ASIA PACIFIC PTE. LTD.. The business annual account filing date falls on 31 October and is currently operational with the status of 'Live Company'. The business paid up share capital is SGD 4,100,000, with preference share capital of SGD 0, and other share capital at SGD 0.

In the past 365 days, SUMITOMO PHARMA ASIA PACIFIC PTE. LTD. has received a total of Login to view reported payment review(s). 1 were rated Good and Login to view were rated Poor. The latest review was made on 2023-08-20 and it was reported "Good". The aggregated good payment amount is equivalent to USD 981, and aggregated poor payment amount is equivalent to USD Login to view. Its current payment rating of "A" suggest a healthy payment culture where settlement with stakeholders is always prioritised. Since the business is currently active, it also signals positive financial standing. The appointment of KPMG LLP as auditor indicates that the business is medium to large sized as it is required to meet additional regulatory requirements either due to reported revenue or assets exceeding SGD 10 million or has more than 50 employees in the previous two fiscal years.

SUMITOMO PHARMA ASIA PACIFIC PTE. LTD. is not yet a Prompt Payment Initiative Signatory.

Last updated on 30 April 2023